Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17614918 | 0.90 | MGLL (0.33) | — | |
| SCHEMBL22717308 | 0.79 | ESR1 (0.39) | ESR1ESR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13016375 | 0.73 | ESR1 (0.45) | ESR1ESR2ACHEMAPTKDM4E | |
| SCHEMBL23639129 | 0.73 | MAP2 (0.38) | ESR1ESR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13016368 | 0.73 | ENPP1 (0.36) | ESR1ESR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL22717148 | 0.73 | ESR1 (0.48) | ESR1ESR2ACHEMAPTKDM4E | |
| SCHEMBL27902695 | 0.67 | ESR1 (0.39) | ESR1ESR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL295908 | 0.66 | ESR1 (0.46) | ESR1ESR2ACHEMAPTKDM4E | |
| SCHEMBL3783517 | 0.66 | ESR1 (0.37) | ESR1ESR2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21821352 | 0.65 | CYP1A2 (0.46) | ESR1ESR2CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10014475-B2 | Graphene nanoribbons as semiconductors for organic thin film transistors | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-20160087212-A1 | GRAPHENE NANORIBBONS AS SEMICONDUCTORS FOR ORGANIC THIN FILM TRANSISTORS | CRESTLINE DIRECT FINANCE, L.P. | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10014475-B2 | Graphene nanoribbons as semiconductors for organic thin film transistors | STRA6, OR10J3, EPCAM | ESR1 2134/4885ESR2 2243/4885CYP1A2 2294/4885 |
| US-20160087212-A1 | GRAPHENE NANORIBBONS AS SEMICONDUCTORS FOR ORGANIC THIN FILM TRANSISTORS | STRA6, OR10J3, EPCAM | ESR1 2134/4885ESR2 2243/4885CYP1A2 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.